Is resistance useless? Multidrug resistance and collateral sensitivity. - Wikidata - awgldk - TriplyDB

Is resistance useless? Multidrug resistance and collateral sensitivity.

Is resistance useless? Multidrug resistance and collateral sensitivity.

http://www.wikidata.org/entity/Q37414081

about

Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes Ten things you should know about protein kinases: IUPHAR Review 14 MVP and vaults: a role in the radiation response Small and Innovative Molecules as New Strategy to Revert MDR Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2)The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitro Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306 Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Multidrug resistance-selective antiproliferative activity of Piper amide alkaloids and synthetic analogues Thyroid hormone and P-glycoprotein in tumor cells.Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.Collateral sensitivity as a strategy against cancer multidrug resistance.Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination Antitumor Agents 291 Expanded B-Ring Modification Study of 6,8,8-Triethyl Desmosdumotin B Analogues as Multidrug-Resistance Selective Agents Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.Starvation, detoxification, and multidrug resistance in cancer therapy Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy Mechanisms and insights into drug resistance in cancer Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.Cost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos.ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.Pharmacogenomic Characterization and Isobologram Analysis of the Combination of Ascorbic Acid and Curcumin-Two Main Metabolites of Curcuma longa-in Cancer Cells.Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.Investigational ABC transporter inhibitors.Sorcin, a potential therapeutic target for reversing multidrug resistance in cancer.MFS transporters required for multidrug/multixenobiotic (MD/MX) resistance in the model yeast: understanding their physiological function through post-genomic approaches.Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel.

P2860

Q24289008-8E0B7546-84BC-4898-9E63-6F193639980B Q26849417-0C9073EF-AFF2-4727-AC3E-D0EA05EFD9D0 Q26865123-F74B42FC-71DA-476A-8863-4E722E029F15 Q27012455-997DADB6-CC8C-4926-9527-0C7852DE4D80 Q27030815-7A2106E4-3966-4AD9-8502-1050AFBF6259 Q28084270-EB6E620B-6DEE-408A-99F6-55AFACF78836 Q28482464-DE285004-95F4-4317-B611-21325D16B05D Q28548419-2CCABB10-D2D8-490E-9E0D-32AE5B2C910B Q28550120-131C260A-1F00-44FF-B0D9-6347636165AB Q33567098-CC9C65FB-8DD2-4350-B727-93E0A26E65E5 Q33682922-7FCACE27-24AD-4E5A-9DDE-638EC935BB1F Q33763765-0A5D8945-861C-4EB5-83FE-322911690F93 Q33802897-D3B8F094-D8D2-4D06-B7BA-A6EBB7D11EF9 Q33985320-974238D7-BFB3-425B-B3F8-2FD78AAEE27A Q34065942-9AF17B1A-DBE1-4E89-BD49-499352BA3D36 Q34153747-96078606-202E-4879-8794-6295E0D8C78A Q34625215-BD3E9354-DE11-4C12-9D79-95AB58122446 Q35057879-306CB248-8879-4FCE-AA02-40C0C1545FB9 Q35197426-12773225-E42B-4F87-BFAE-D762671EC12D Q35250590-54386197-DE84-454F-9159-B8ECD115867D Q35447223-5FB8DCA1-F4DC-4A2D-B621-FC028F31E88C Q35528557-60EC79A3-DCB9-46FF-B443-A1B4C955AD80 Q35946556-E32FC69E-E601-43B9-8E55-3F5CEEC39963 Q36260937-7FA12614-B79F-4E47-9547-A6180568C6E2 Q36405766-FEA0E875-E4BE-452C-AB88-B63ACE673FAA Q36413446-3F4B1318-6218-4621-9D6E-B9661B512C91 Q36509179-12E2B47A-A485-4C41-A099-37AF9F3D5E57 Q36585797-468A29BF-ABF1-418A-A0E5-FC056B47731E Q36614054-FD918D69-B970-476B-859F-48ACF1BC1CBB Q36614947-CDE7C786-2A9C-4116-AE37-57A62300A990 Q36682301-AB84F3B8-1DDB-48CF-A22B-B8CF44945EE3 Q37168584-46E247B1-5CB4-4697-B2C2-710DE88932BB Q37200589-045A7C9D-3BE4-4766-AAF4-48987094075E Q37285224-4D54879A-37DE-41B2-8FE6-D1E607F66BD1 Q37620415-099EDD42-97CF-4AA6-A26C-FA86FF9502F1 Q37740126-25334119-AF5B-4655-B5AF-F12430A5AB1A Q38001734-EAB1CFC9-C42E-43CD-96EC-61748D81E3ED Q38018959-D941279C-4CC4-45F6-AB83-9D91F700A9FC Q38213387-7FB836F4-E24B-4B99-BE51-804D0154BE95 Q38665011-9D535C19-9055-4934-BE78-13DC70381DF2

P2860

Is resistance useless? Multidrug resistance and collateral sensitivity.

http://www.wikidata.org/entity/Q37414081

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Is resistance useless? Multidrug resistance and collateral sensitivity.

@en

Is resistance useless? Multidrug resistance and collateral sensitivity.

@nl

type

label

Is resistance useless? Multidrug resistance and collateral sensitivity.

@en

Is resistance useless? Multidrug resistance and collateral sensitivity.

@nl

prefLabel

Is resistance useless? Multidrug resistance and collateral sensitivity.

@en

Is resistance useless? Multidrug resistance and collateral sensitivity.

@nl

P1433

Q37414081-299053D8-BCE5-4AF6-B21C-5BC59345691F

P1476

Q37414081-0E21B4AE-1A1A-464A-A800-29E5E2B5E562

P2093

Q37414081-814952AC-7988-4D3E-8071-0B26E30B01D2

Q37414081-870CEADC-8A96-4F51-90A3-7F204CA4D757

Q37414081-C15F4DE4-F879-434F-841B-9DA6F096F4B9

P2860

Q37414081-02CDEDEF-47AC-41B0-9B14-2FD001620F59

Q37414081-04CC1D75-DC22-4D19-ADC8-A5E34CA0F474

Q37414081-0A389038-5570-4D66-8138-65F723F0B4B0

Q37414081-10434D15-9434-40B9-9ED5-59495B5F5CC5

Q37414081-10D3892C-1956-4B3C-ACE9-FE1ACF63487D

Q37414081-1188F0D6-20B1-4397-AD9F-840EEDE64354

Q37414081-12B0D1D4-B343-4A0A-B938-795AA6EBE6BF

Q37414081-14E97778-90DD-4549-BB66-64AAAE1F05C4

Q37414081-16CB2A5D-852D-46EB-B78A-0FA65A4F9E40

Q37414081-1CEA5870-1CCD-43A9-BC76-68BD17ED7D3A

P304

Q37414081-8B597480-5B47-4C41-A977-98FED280F628

P31

Q37414081-5D70E528-52FA-45C5-882D-D9BDFC9B9CA3

P356

Q37414081-C4AE4223-28DF-4414-88F1-1DE792A9BB1D

P433

Q37414081-D19C8B32-9E20-4504-B1DA-CF24056BC4A9

P478

Q37414081-BF7935FA-8C63-4EA3-A46B-C292929444C2

P577

Q37414081-8D79B1D1-FBF4-4947-BA69-FDC8FBBBE18D

P5875

Q37414081-501403A8-0FC8-4717-9AF0-220F5D491ADF

P698

Q37414081-99FBF136-386D-414A-987E-2C1424FCE3DA

P921

Q37414081-0E627996-4902-4EF9-B855-7A6E5D583148

P932

Q37414081-9C3E197B-069C-49C0-B20D-4E7612AD6DCD

P356

J.TIPS.2009.07.003

P1433

Trends in Pharmacological Sciences

P1476

Is resistance useless? Multidrug resistance and collateral sensitivity.

@en

P2093

Matthew D Hall

http://www.w3.org/2001/XMLSchema#string

Michael M Gottesman

http://www.w3.org/2001/XMLSchema#string

Misty D Handley

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

Localization of the primary metabolic block produced by 2-deoxyglucose

A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine

Mechanisms of cancer drug resistance

Principles of cancer therapy: oncogene and non-oncogene addiction

Targeting multidrug resistance in cancer

Screening of an annotated compound library for drug activity in a resistant myeloma cell line.

A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.

Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane.

P304

546-556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TIPS.2009.07.003

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26819683

http://www.w3.org/2001/XMLSchema#string

P698

19762091

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

2774243

http://www.w3.org/2001/XMLSchema#string